NCT01488890View on ClinicalTrials.gov

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

December 6, 2011

Primary Completion Date

September 27, 2013

Study Completion Date

September 27, 2013

Conditions
DengueDengue FeverDengue Hemorrhagic FeverYellow Fever
Interventions
BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

0.5 mL, Subcutaneous

BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

0.5 mL, Subcutaneous

BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

0.5 mL, Subcutaneous

BIOLOGICAL

Yellow Fever

0.5 mL, Subcutaneous

Trial Locations (7)

20910

Silver Spring

32216

Jacksonville

35007

Alabaster

65802

Springfield

84088

West Jordan

89104

Las Vegas

95816

Sacramento

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01488890 - Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine | Biotech Hunter | Biotech Hunter